Supriya Lifescience Limited — Others, 03-07-2025: Disclosure under SEBI Takeover Regulations

Supriya Lifescience Limited’s promoter and promoter group, including Satish Waman Wagh and related entities, have confirmed that they have not created any encumbrance on their shares during the financial year. This indicates no new pledges or charges against promoter holdings, which supports shareholding stability and reduces concerns of forced selling or liquidity pressure on the stock. This clarity benefits shareholders by affirming promoter confidence and maintaining corporate governance transparency.